Gov't authorizes COVID-19 vaccine from Pfizer and BioNTech

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine.

The Health Sciences Authority has authorised Pfizer and BioNTech SE’s updated COVID-19 vaccine tailored to the Omicron JN.1 variant, making Singapore the first Southeast Asian country to receive full approval.

The approval was based on manufacturing and non-clinical immunogenicity evaluation, leveraging on previous clinical data to support the safety and effectiveness of Pfizer-BioNTech’s COVID-19 vaccines.

The non-clinical data showed that the Omicron JN.1-adapted vaccine responds better against the circulating variant compared to the Omicron XBB.1.5-adapted vaccine.

The vaccine is expected to enhance protection against current strains, particularly for high-risk populations such as the elderly and individuals with pre-existing conditions.

Follow the link for more news on

Pfizer

COVID-19

Also Read

Hyphens Pharma gets exclusive rights to distribute European autoinjector

SATA CommHealth unveils new community clinic at Beach Road

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit